[38] revealed that depth of invasion, lymph node metastasis, and LBVI independently influenced prognosis in stage I gastric cancer, and in their report, patients with stage I GC having lymphovascular invasion and stage II GC had similar survival outcomes; this finding suggests that
adjuvant chemotherapy is suitable for stage I patients with moderate to severe lymphovascular invasion.
In the interdisciplinary tumour conference a preliminary decision was made as to whether
adjuvant chemotherapy would be beneficial and acceptable on the basis of the previously known risk profile.
The value of the risk score was to indicate the high risk of poor prognosis and give the recommendation for
adjuvant chemotherapy. And the groups divided by the DFS risk score was similar to the above shown in [Table 5] and [Figure 2].
Although several studies have shown that blood-based biomarkers such as cancer antigen 15-3 (CA 15-3) or carcinoembryonic antigen (CEA) can provide prognostic information in newly diagnosed patients with breast cancer, use of these biomarkers has not to date been shown to guide decision-making on the use of
adjuvant chemotherapy. Consequently, measurement of blood-based biomarkers is not generally recommended for treatment decision-making in patients with early breast cancer.
Dose and dose intensity of
adjuvant chemotherapy for stage II, node-positive breast carcinoma.
(3.) Visbal AL, Leighl NB, Feld R, et al:
Adjuvant chemotherapy for early stage non-small cell lung cancer.
Late effects of high-dose
adjuvant chemotherapy on white and gray matter in breast cancer survivors: Converging results from multimodal magnetic resonance imaging.
Cancer care ontario and American society of clinical oncology
adjuvant chemotherapy and adjuvant radiation therapy for stages I-III A respectable non-small-cell lung cancer guideline.
Specifically, we examine the factors associated with receiving guideline-concordant (1)
adjuvant chemotherapy, (2) adjuvant radiation therapy, and (3) adjuvant hormonal therapy, considered both individually and for all adjuvant therapies jointly, among SWGA breast cancer patients.
In order to find appropriate articles about
adjuvant chemotherapy in rectal cancer, Ovid Medline (1946 to February 2014), PubMed, and the Cochrane library were used as online databases.
Eighteen patients received neoadjuvant chemotherapy and/or radiation, with four of these patients eventually receiving additional therapy after pneumonectomy; eight patients received
adjuvant chemotherapy and/or radiation, and ten patients received surgery alone (Table 1).
The use of
adjuvant chemotherapy (AC) following surgical resection of colorectal cancer has been shown to improve outcome [2-5].
